Abstract 480P
Background
The primary cause of death in gastric cancer patients is disease recurrence. A scoring system capable of predicting patient recurrence beyond TNM staging could greatly assist in formulating effective treatment plans. In this study, we aimed to design a recurrence prediction scoring system by selecting factors known to be associated with gastric cancer recurrence from prior research.
Methods
This retrospective study examined 296 patients diagnosed with Stage II/III gastric cancer who had undergone complete surgical resection and adjuvant chemotherapy over the past 12 years. We investigated seven variables in these patients: HER2, EBV, p53, Lauren classification, E-cadherin, MSI status, and the systemic inflammation response index (SIRI), calculated as Neutrophil count * Monocyte count / Lymphocyte count.
Results
While other factors did not exhibit statistical significance, SIRI showed a positive correlation with gastric cancer recurrence risk, confirmed through Cox regression testing (HR of 1.231, 95% CI of 1.04-1.45). Additionally, we explored the proportional relationship between SIRI and gastric cancer recurrence; higher SIRI values were associated with shorter times to recurrence, demonstrated through statistically significant linear regression analysis (p-value of 0.044 and β-value of -0.225).
Conclusions
This study acknowledges the limitation of the small sample size, and with a larger patient cohort, more statistically meaningful factors beyond SIRI are anticipated. The study's significance lies in employing SIRI as a continuous variable to establish its proportional relationship with gastric cancer recurrence. Higher SIRI values are linked to shorter timeframes to recurrence, underscoring its importance in treatment planning.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.